AMDX-2011P
Phase 2Small molecule
AMDX-2011P is one of 26 small molecule programs targeting Glaucoma. It is currently in Phase 2.
1
Indications
3
Total Trials
3
Active Trials
25
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
182 competitors in Glaucoma
#DrugCompanyPhaseTrials
1Lucentis
RochePhase 3
Namenda
AbbViePhase 3
Viagra
VViatris Specialty LLC
Phase 3
Zioptan
MMeitheal
Phase 3
Prostaglandin
LLaboratoires Thea
Phase 3
Gingko Biloba
Boehringer IngelheimPhase 3
T2345
LLaboratoires Thea
Phase 3
Alphagan
AbbViePreclinical
Prostigmin
Merck & Co.Preclinical
Aquasol a
BBandim Health Project
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for AMDX-2011P. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company
- AAmydis Inc.